IFN-γ can stimulate T cells (85), and antigen presenting cells (APCs) to produce B lymphocyte-stimulating factor (BLyS) (86), which is essential for B-cell differentiation, proliferation and survival, regulates B-cell generation and maturation (87, 88), and has been identified as a therapeutic target for SLE. The gene discussed is IFNG; the disease is systemic lupus erythematosus.